Screener
Sionna Therapeutics SION Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 2,820 | 3,000 |
| Other income | — | 177 |
| Total other income | 2,820 | 3,177 |
| Net loss | $(26,779) | $(16,482) |
| Net loss per share, basic and diluted | $(0.60) | $(0.62) |
| Weighted-average common shares outstanding, basic and diluted | 44,921,984 | 26,596,059 |
| Comprehensive loss: | ||
| Net loss | $(26,779) | $(16,482) |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's business segments — net loss?
- Sionna Therapeutics (SION) reported business segments — net loss of -$26.78M in Q1 2026.
- How has Sionna Therapeutics's business segments — net loss changed year-over-year?
- Sionna Therapeutics's business segments — net loss decreased by 62.5% year-over-year, from -$16.48M to -$26.78M.
- What does business segments — net loss mean?
- Represents the total financial loss generated by a specific business segment after accounting for all allocated revenues and operating expenses. For clinical-stage companies, this metric serves as a primary indicator of the segment's current cash burn rate and financial sustainability. It highlights the extent to which the segment's activities are funded by corporate capital rather than self-generated revenue.
Ask your AI about Sionna Therapeutics's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude